StockData
GT Biopharma, Inc. logo

GT Biopharma, Inc. (GTBP) stock

GTBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 5/30
$3.18−0.35 (-10.04%)

Close on Nov 17, 2026Market cap $143.45MP/E –Yield –

Earnings

GT Biopharma's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of GT Biopharma's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2025ended Sep 30, 2025Nov 14, 2025before the open–––Release
Q3 FY2018ended Sep 30, 2018Nov 15, 2018before the open–––Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

GT Biopharma has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When GT Biopharma puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases GT Biopharma filed with the SEC as exhibits to Form 8-K or 6-K

See a number that looks wrong?